Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00370227 | Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine | PHASE3 | COMPLETED | 390 | — | — | Oct 1, 2006 | Mar 1, 2007 | Oct 28, 2016 | 8 | Finland |
| Name | Type | Description |
|---|---|---|
| 10 valent pneumococcal conjugate (vaccine) | BIOLOGICAL | - |
Inclusion Criteria: * a healthy male or female, 12-14 months of age at the time of first vaccination, who received at least one dose of pneumococcal conjugate vaccine during study 105553 and with written informed consent obtained from the parent/guardian of the subject. Exclusion Criteria: * use ...